lanthanum has been researched along with CKD-MBD in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, A; Xu, G; Zhao, L | 1 |
| Kobayashi, M; Takeda, H; Tatemichi, S; Yaguchi, A | 1 |
| Craig, JC; Elder, GJ; Natale, P; Palmer, SC; Ruospo, M; Strippoli, GF; Vecchio, M | 1 |
| Bhargava, R; Brenchley, P; Hann, M; Hurst, H; Hutchison, AJ; Kalra, PA | 1 |
| Fukagawa, M; Koizumi, M; Komaba, H | 1 |
| Fan, J; Li, Z; Wen, J; Zhang, C | 1 |
| Confer, S; Malluche, HH; Mawad, H; Monier-Faugere, MC; Pratt, RD; Siami, GA; Smith, M; Swanepoel, C; Wang, GH | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Malluche, HH; Mawad, H; Monier-Faugere, MC | 1 |
| Alonso, M; Andrés, E; Ballarín, J; Bover, J; Canal, C; Farré, N; Olaya, MT; Quílez, B | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Blanco Rodríguez, I; Pobes Martínez de Salinas, A; Quiñones Ortiz, L; Suárez Laurés, A | 1 |
| Arisaka, H; Nakaoka, A; Shigematsu, T; Tokumoto, A | 1 |
| Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Balducci, A; Coen, G; Curic, S; D'Haese, PC; De Broe, ME; Dimkovic, N; Djukanovic, L; Ferreira, A; Freemont, TJ; Hutchison, A; Pejanovic, S; Popovic, M; Sikole, A; Spasovski, GB; Sulkova, S; Sulowicz, W; Swanepoel, C; Torres, A | 1 |
| Freemont, T; Malluche, HH | 1 |
| Behets, GJ; Bervoets, AR; Cox, AG; D'Haese, PC; De Broe, ME; Denton, J; Oste, L; Salomé, M; Verberckmoes, SC | 1 |
| Denton, J; Freemont, AJ; Hoyland, JA | 1 |
| D'Haese, PC; De Broe, ME; Freemont, T; Gelev, S; Gill, M; Jones, C; Masin-Spasovska, J; Sikole, A; Spasovski, GB; Webster, I | 1 |
| Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
| Hutchison, AJ | 1 |
9 review(s) available for lanthanum and CKD-MBD
| Article | Year |
|---|---|
Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Lanthanum; Observational Studies as Topic; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer; Treatment Outcome | 2021 |
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Adult; Aged; Calcium; Calcium Compounds; Cause of Death; Chelating Agents; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Humans; Hypercalcemia; Iron Compounds; Lanthanum; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer | 2018 |
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Topics: Animals; Binding, Competitive; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expression Regulation; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Kidney Tubules; Klotho Proteins; Lanthanum; Models, Biological; Parathyroid Glands; Parathyroid Hormone; Phosphates; Polyamines; Receptor, Fibroblast Growth Factor, Type 1; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency | 2013 |
Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Topics: China; Chronic Kidney Disease-Mineral and Bone Disorder; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Incidence; Lanthanum; Male; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
Effects of treatment of renal osteodystrophy on bone histology.
Topics: Bone and Bones; Bone Remodeling; Calcification, Physiologic; Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Lanthanum; Naphthalenes; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer; Vitamin D | 2008 |
Update on the treatment of chronic kidney disease-mineral and bone disorder.
Topics: Aluminum Compounds; Calcinosis; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Dietetics; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Nephrology; Nutrition Assessment; Nutritive Value; Parathyroidectomy; Patient Care Team; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Vitamin D | 2009 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
6 trial(s) available for lanthanum and CKD-MBD
| Article | Year |
|---|---|
A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Patient Acceptance of Health Care; Patient Dropouts; Phosphates; Phosphorus, Dietary; Renal Dialysis; Sepsis; Sevelamer | 2019 |
Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.
Topics: Adult; Analysis of Variance; Biomarkers; Bone Remodeling; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Treatment Outcome | 2008 |
Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Topics: Adult; Aged; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Young Adult | 2011 |
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis | 2003 |
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Calcitriol; Calcium; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Renal Dialysis; Treatment Outcome | 2005 |
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Calcifediol; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Follow-Up Studies; Humans; Ilium; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
7 other study(ies) available for lanthanum and CKD-MBD
| Article | Year |
|---|---|
PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Ferric Compounds; Kidney Failure, Chronic; Lanthanum; Male; Parathyroid Hormone; Phosphorus; Rats; Sevelamer; Treatment Outcome | 2017 |
[Intestinal pseudo-occlusion due to lanthanum carbonate].
Topics: Aged; Chelating Agents; Chelation Therapy; Chronic Kidney Disease-Mineral and Bone Disorder; Colonic Diseases; Humans; Hyperphosphatemia; Intestinal Pseudo-Obstruction; Ischemia; Kidney; Kidney Failure, Chronic; Lanthanum; Laparotomy; Male; Phosphates; Radiography; Renal Dialysis | 2010 |
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Topics: Adult; Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cost Savings; Health Care Costs; Hemodialysis Solutions; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Technology Assessment, Biomedical | 2011 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate.
Topics: Adult; Bone Remodeling; Calcification, Physiologic; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Histological Techniques; Humans; Ilium; Lanthanum; Male; Osteocytes; Prospective Studies | 2005 |
Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
Topics: Administration, Oral; Animals; Bone and Bones; Bone Density; Chronic Kidney Disease-Mineral and Bone Disorder; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Rats; Rats, Wistar; Spectrometry, X-Ray Emission; Tissue Distribution | 2005 |
Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy.
Topics: Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Lanthanum; Peritoneal Dialysis; Phosphates; Vitamin D | 1999 |